The present invention generally relates to kits for detecting Mycobacterium avium subspecies paratuberculosis (MAP) infection and biomarkers correlated with MAP-associated diseases or disorders. The present method also relates to methods of diagnosing a subject with a MAP-associated autoimmune disease or disorder and/or determining the treatment course of a subject diagnosed with a MAP-associated autoimmune disease or disorder.

A highly efficient and non-invasive automated diagnosis method of some inflammatory bowel diseases, such as Ulcerative Colitis (UC) and Crohn's Disease (CD), which always allows to avoid duodenal biopsy. Such a method is based on spectroscopic analysis by Raman technique, which operates directly on a protein extract of feces, and reduces the burden of the diagnosis, simultaneously being preferably useful for the automated distinction between Ulcerative Colitis (UC) and Crohn's Disease (CD).

A highly efficient and non-invasive automated diagnosis method of some inflammatory bowel diseases, such as Ulcerative Colitis (UC) and Crohn's Disease (CD), which always allows to avoid duodenal biopsy. Such a method is based on spectroscopic analysis by Raman technique, which operates directly on a protein extract of feces, and reduces the burden of the diagnosis, simultaneously being preferably useful for the automated distinction between Ulcerative Colitis (UC) and Crohn's Disease (CD).

The present invention provides compounds and methods targeting human interleukin-19, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of immune-mediated diseases including psoriasis, atopic dermatitis, psoriatic arthritis, bronchial asthma and diabetic nephropathy.

Provide are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.

Provide are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.

There are provided a method and a kit for evaluating allergen inactivators, the method and kit making it possible to carry out a precise and reproducible evaluation irrespective of the type of test drug, or the type of accompanying components thereof, that is subject to the evaluation.

A method for evaluating allergen inactivators, said method being characterized by comprising: a step for preparing an allergen-supporting membrane configured by supporting allergens on a membrane for supporting allergens; a step for treating the allergen-supporting membrane using a test drug; a step for washing the allergen-supporting membrane treated using the test drug, and subsequently treating the allergen-supporting membrane using antibodies specific to the allergens; a step for washing the allergen-supporting membrane treated using the antibodies specific to the allergens, and subsequently detecting the specific antibodies bound to the allergens; and a step for assessing the extent to which the allergens are inactivated by the test drug based on the detected quantity of the specific antibodies.

There are provided a method and a kit for evaluating allergen inactivators, the method and kit making it possible to carry out a precise and reproducible evaluation irrespective of the type of test drug, or the type of accompanying components thereof, that is subject to the evaluation.

A method for evaluating allergen inactivators, said method being characterized by comprising: a step for preparing an allergen-supporting membrane configured by supporting allergens on a membrane for supporting allergens; a step for treating the allergen-supporting membrane using a test drug; a step for washing the allergen-supporting membrane treated using the test drug, and subsequently treating the allergen-supporting membrane using antibodies specific to the allergens; a step for washing the allergen-supporting membrane treated using the antibodies specific to the allergens, and subsequently detecting the specific antibodies bound to the allergens; and a step for assessing the extent to which the allergens are inactivated by the test drug based on the detected quantity of the specific antibodies.

A method and a device are useful for detecting a binding of autoantibodies from a patient sample to double-stranded deoxyribonucleic acid (DNA) using Crithidia luciliae cells by fluorescence microscopy and by digital image processing.

A method and a device are useful for detecting a binding of autoantibodies from a patient sample to double-stranded deoxyribonucleic acid (DNA) using Crithidia luciliae cells by fluorescence microscopy and by digital image processing.